Incannex Healthcare (IXHL) Competitors

$3.99 +0.14 (+3.71%)

As of 01:35 PM Eastern

IXHL vs. MDWD, SLGL, NKTX, CNTX, and REPL

Should you buy Incannex Healthcare stock or one of its competitors? MarketBeat compares Incannex Healthcare with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Incannex Healthcare include MediWound (MDWD), Sol-Gel Technologies (SLGL), Nkarta (NKTX), Context Therapeutics (CNTX), and Replimune Group (REPL). These companies are all part of the "pharmaceutical products" industry.

How does Incannex Healthcare compare to MediWound?

Incannex Healthcare (NASDAQ:IXHL) and MediWound (NASDAQ:MDWD) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, risk, media sentiment, valuation, earnings, profitability and institutional ownership.

Incannex Healthcare has a beta of 7.22, indicating that its share price is 622% more volatile than the broader market. Comparatively, MediWound has a beta of 0.21, indicating that its share price is 79% less volatile than the broader market.

Incannex Healthcare has a net margin of 0.00% compared to MediWound's net margin of -140.80%. MediWound's return on equity of -65.79% beat Incannex Healthcare's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Incannex Healthcare	N/A	-114.95%	-103.38%
MediWound	-140.80%	-65.79%	-30.16%

In the previous week, Incannex Healthcare had 4 more articles in the media than MediWound. MarketBeat recorded 6 mentions for Incannex Healthcare and 2 mentions for MediWound. MediWound's average media sentiment score of 0.63 beat Incannex Healthcare's score of 0.59 indicating that MediWound is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Incannex Healthcare	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
MediWound	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

0.4% of Incannex Healthcare shares are held by institutional investors. Comparatively, 46.8% of MediWound shares are held by institutional investors. 1.3% of Incannex Healthcare shares are held by insiders. Comparatively, 9.2% of MediWound shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

MediWound has higher revenue and earnings than Incannex Healthcare. MediWound is trading at a lower price-to-earnings ratio than Incannex Healthcare, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Incannex Healthcare	$90K	529.29	-$46.88M	-$8.41	N/A
MediWound	$16.96M	12.67	-$23.88M	-$2.10	N/A

MediWound has a consensus price target of $35.00, indicating a potential upside of 109.22%. Given MediWound's stronger consensus rating and higher probable upside, analysts plainly believe MediWound is more favorable than Incannex Healthcare.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Incannex Healthcare	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
MediWound	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Summary

MediWound beats Incannex Healthcare on 11 of the 16 factors compared between the two stocks.

How does Incannex Healthcare compare to Sol-Gel Technologies?

Incannex Healthcare (NASDAQ:IXHL) and Sol-Gel Technologies (NASDAQ:SLGL) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, risk, media sentiment, valuation, earnings, profitability and institutional ownership.

Incannex Healthcare has a beta of 7.22, indicating that its share price is 622% more volatile than the broader market. Comparatively, Sol-Gel Technologies has a beta of 1.16, indicating that its share price is 16% more volatile than the broader market.

Sol-Gel Technologies has a consensus price target of $110.00, indicating a potential upside of 59.24%. Given Sol-Gel Technologies' stronger consensus rating and higher probable upside, analysts plainly believe Sol-Gel Technologies is more favorable than Incannex Healthcare.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Incannex Healthcare	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Sol-Gel Technologies	0 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.33

Incannex Healthcare has a net margin of 0.00% compared to Sol-Gel Technologies' net margin of -31.60%. Sol-Gel Technologies' return on equity of -24.29% beat Incannex Healthcare's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Incannex Healthcare	N/A	-114.95%	-103.38%
Sol-Gel Technologies	-31.60%	-24.29%	-18.73%

In the previous week, Incannex Healthcare had 4 more articles in the media than Sol-Gel Technologies. MarketBeat recorded 6 mentions for Incannex Healthcare and 2 mentions for Sol-Gel Technologies. Incannex Healthcare's average media sentiment score of 0.59 beat Sol-Gel Technologies' score of 0.44 indicating that Incannex Healthcare is being referred to more favorably in the media.

Company	Overall Sentiment
Incannex Healthcare	Positive
Sol-Gel Technologies	Neutral

0.4% of Incannex Healthcare shares are held by institutional investors. Comparatively, 26.2% of Sol-Gel Technologies shares are held by institutional investors. 1.3% of Incannex Healthcare shares are held by insiders. Comparatively, 66.5% of Sol-Gel Technologies shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Sol-Gel Technologies has higher revenue and earnings than Incannex Healthcare. Sol-Gel Technologies is trading at a lower price-to-earnings ratio than Incannex Healthcare, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Incannex Healthcare	$90K	529.29	-$46.88M	-$8.41	N/A
Sol-Gel Technologies	$19.39M	10.01	-$6.13M	-$2.23	N/A

Summary

Sol-Gel Technologies beats Incannex Healthcare on 10 of the 16 factors compared between the two stocks.

How does Incannex Healthcare compare to Nkarta?

Nkarta (NASDAQ:NKTX) and Incannex Healthcare (NASDAQ:IXHL) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, risk, valuation, dividends, media sentiment, profitability, earnings and institutional ownership.

Nkarta presently has a consensus price target of $11.33, indicating a potential upside of 288.66%. Given Nkarta's stronger consensus rating and higher possible upside, research analysts clearly believe Nkarta is more favorable than Incannex Healthcare.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nkarta	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Incannex Healthcare	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Nkarta and Nkarta both had 6 articles in the media. Nkarta's average media sentiment score of 0.81 beat Incannex Healthcare's score of 0.59 indicating that Nkarta is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nkarta	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Incannex Healthcare	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Nkarta's return on equity of -29.75% beat Incannex Healthcare's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nkarta	N/A	-29.75%	-23.43%
Incannex Healthcare	N/A	-114.95%	-103.38%

Nkarta has a beta of 0.88, indicating that its stock price is 12% less volatile than the broader market. Comparatively, Incannex Healthcare has a beta of 7.22, indicating that its stock price is 622% more volatile than the broader market.

Incannex Healthcare has higher revenue and earnings than Nkarta. Nkarta is trading at a lower price-to-earnings ratio than Incannex Healthcare, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nkarta	N/A	N/A	-$104.08M	-$1.40	N/A
Incannex Healthcare	$90K	529.29	-$46.88M	-$8.41	N/A

80.5% of Nkarta shares are held by institutional investors. Comparatively, 0.4% of Incannex Healthcare shares are held by institutional investors. 8.4% of Nkarta shares are held by insiders. Comparatively, 1.3% of Incannex Healthcare shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Nkarta beats Incannex Healthcare on 9 of the 13 factors compared between the two stocks.

How does Incannex Healthcare compare to Context Therapeutics?

Incannex Healthcare (NASDAQ:IXHL) and Context Therapeutics (NASDAQ:CNTX) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, risk, analyst recommendations, profitability, earnings, media sentiment, institutional ownership and valuation.

Context Therapeutics has a consensus price target of $6.60, indicating a potential upside of 177.89%. Given Context Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Context Therapeutics is more favorable than Incannex Healthcare.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Incannex Healthcare	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Context Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

In the previous week, Context Therapeutics had 11 more articles in the media than Incannex Healthcare. MarketBeat recorded 17 mentions for Context Therapeutics and 6 mentions for Incannex Healthcare. Context Therapeutics' average media sentiment score of 1.01 beat Incannex Healthcare's score of 0.59 indicating that Context Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Incannex Healthcare	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Context Therapeutics	3 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Context Therapeutics' return on equity of -59.95% beat Incannex Healthcare's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Incannex Healthcare	N/A	-114.95%	-103.38%
Context Therapeutics	N/A	-59.95%	-54.78%

Incannex Healthcare has a beta of 7.22, indicating that its share price is 622% more volatile than the broader market. Comparatively, Context Therapeutics has a beta of 1.57, indicating that its share price is 57% more volatile than the broader market.

Context Therapeutics has lower revenue, but higher earnings than Incannex Healthcare. Context Therapeutics is trading at a lower price-to-earnings ratio than Incannex Healthcare, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Incannex Healthcare	$90K	529.29	-$46.88M	-$8.41	N/A
Context Therapeutics	N/A	N/A	-$36.12M	-$0.42	N/A

0.4% of Incannex Healthcare shares are owned by institutional investors. Comparatively, 14.0% of Context Therapeutics shares are owned by institutional investors. 1.3% of Incannex Healthcare shares are owned by company insiders. Comparatively, 4.8% of Context Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Context Therapeutics beats Incannex Healthcare on 12 of the 15 factors compared between the two stocks.

How does Incannex Healthcare compare to Replimune Group?

Incannex Healthcare (NASDAQ:IXHL) and Replimune Group (NASDAQ:REPL) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, risk, analyst recommendations, profitability, earnings, media sentiment, institutional ownership and valuation.

Incannex Healthcare has a beta of 7.22, indicating that its share price is 622% more volatile than the broader market. Comparatively, Replimune Group has a beta of 0.12, indicating that its share price is 88% less volatile than the broader market.

0.4% of Incannex Healthcare shares are owned by institutional investors. Comparatively, 92.5% of Replimune Group shares are owned by institutional investors. 1.3% of Incannex Healthcare shares are owned by company insiders. Comparatively, 5.2% of Replimune Group shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, Incannex Healthcare had 2 more articles in the media than Replimune Group. MarketBeat recorded 6 mentions for Incannex Healthcare and 4 mentions for Replimune Group. Incannex Healthcare's average media sentiment score of 0.59 beat Replimune Group's score of 0.37 indicating that Incannex Healthcare is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Incannex Healthcare	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Replimune Group	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Replimune Group's return on equity of -102.69% beat Incannex Healthcare's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Incannex Healthcare	N/A	-114.95%	-103.38%
Replimune Group	N/A	-102.69%	-72.22%

Replimune Group has a consensus price target of $4.75, indicating a potential upside of 3.37%. Given Replimune Group's stronger consensus rating and higher possible upside, analysts clearly believe Replimune Group is more favorable than Incannex Healthcare.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Incannex Healthcare	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Replimune Group	4 Sell rating(s)	6 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.60

Incannex Healthcare has higher revenue and earnings than Replimune Group. Replimune Group is trading at a lower price-to-earnings ratio than Incannex Healthcare, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Incannex Healthcare	$90K	529.29	-$46.88M	-$8.41	N/A
Replimune Group	N/A	N/A	-$247.30M	-$3.44	N/A

Summary

Replimune Group beats Incannex Healthcare on 7 of the 13 factors compared between the two stocks.

Get Incannex Healthcare News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IXHL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IXHL vs. The Competition

Export

Metric	Incannex Healthcare	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$47.24M	$3.04B	$6.30B	$12.46B
Dividend Yield	N/A	1.96%	2.79%	5.30%
P/E Ratio	-0.47	18.85	20.92	25.65
Price / Sales	529.29	284.59	551.58	76.73
Price / Cash	N/A	56.53	42.94	55.34
Price / Book	1.93	4.35	9.87	6.72
Net Income	-$46.88M	$72.19M	$3.55B	$333.73M
7 Day Performance	-16.81%	-0.97%	-0.20%	0.40%
1 Month Performance	12.80%	0.05%	1.48%	4.09%
1 Year Performance	-80.99%	45.90%	41.00%	36.52%

Incannex Healthcare Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IXHL Incannex Healthcare	0.5 of 5 stars	$3.99 +3.7%	N/A	+50.4%	$47.24M	$90K	N/A	3	News Coverage Upcoming Earnings
MDWD MediWound	2.1043 of 5 stars	$17.26 +3.8%	$35.00 +102.8%	-18.4%	$213.73M	$16.96M	N/A	80	News Coverage Positive News Upcoming Earnings
SLGL Sol-Gel Technologies	1.9381 of 5 stars	$77.70 +2.8%	$110.00 +41.6%	+865.0%	$212.46M	$19.39M	N/A	50	Analyst Upgrade Short Interest Increase
NKTX Nkarta	3.6008 of 5 stars	$3.02 +3.1%	$11.33 +275.3%	+57.7%	$208.88M	N/A	N/A	140	Earnings Report Analyst Forecast
CNTX Context Therapeutics	3.4629 of 5 stars	$2.30 +1.3%	$6.60 +187.0%	+187.8%	$208.57M	N/A	N/A	7	Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IXHL) was last updated on 5/14/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Incannex Healthcare (IXHL) Competitors

IXHL vs. MDWD, SLGL, NKTX, CNTX, and REPL

How does Incannex Healthcare compare to MediWound?

Summary

How does Incannex Healthcare compare to Sol-Gel Technologies?

Summary

How does Incannex Healthcare compare to Nkarta?

Summary

How does Incannex Healthcare compare to Context Therapeutics?

Summary

How does Incannex Healthcare compare to Replimune Group?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IXHL vs. The Competition

Incannex Healthcare Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Incannex Healthcare (IXHL) Competitors

IXHL vs. MDWD, SLGL, NKTX, CNTX, and REPL

How does Incannex Healthcare compare to MediWound?

Which has more risk and volatility, IXHL or MDWD?

Is IXHL or MDWD more profitable?

Does the media prefer IXHL or MDWD?

Do insiders & institutionals have more ownership in IXHL or MDWD?

Which has higher earnings and valuation, IXHL or MDWD?

Do analysts recommend IXHL or MDWD?

Summary

How does Incannex Healthcare compare to Sol-Gel Technologies?

Which has more risk and volatility, IXHL or SLGL?

Do analysts recommend IXHL or SLGL?

Is IXHL or SLGL more profitable?

Does the media prefer IXHL or SLGL?

Do insiders & institutionals have more ownership in IXHL or SLGL?

Which has higher earnings and valuation, IXHL or SLGL?

Summary

How does Incannex Healthcare compare to Nkarta?

Do analysts recommend NKTX or IXHL?

Does the media prefer NKTX or IXHL?

Is NKTX or IXHL more profitable?

Which has more risk & volatility, NKTX or IXHL?

Which has stronger earnings & valuation, NKTX or IXHL?

Do institutionals & insiders have more ownership in NKTX or IXHL?

Summary

How does Incannex Healthcare compare to Context Therapeutics?

Do analysts rate IXHL or CNTX?

Does the media refer more to IXHL or CNTX?

Is IXHL or CNTX more profitable?

Which has more volatility & risk, IXHL or CNTX?

Which has preferable valuation & earnings, IXHL or CNTX?

Do insiders and institutionals have more ownership in IXHL or CNTX?

Summary

How does Incannex Healthcare compare to Replimune Group?

Which has more volatility & risk, IXHL or REPL?

Do insiders and institutionals have more ownership in IXHL or REPL?

Does the media refer more to IXHL or REPL?

Is IXHL or REPL more profitable?

Do analysts rate IXHL or REPL?

Which has preferable valuation & earnings, IXHL or REPL?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IXHL vs. The Competition

Incannex Healthcare Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools